Comparison · NCT00645099-a8ed374e
Paliperidone ER vs Olanzapine: Number of Patients With Impaired Fasting Glucose
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Paliperidone ER vs Olanzapine: Number of Patients With Impaired Fasting Glucose. Trial comparisons, record NCT00645099-a8ed374e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00645099-a8ed374e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.305 | 0.248 | 0.368 | wilson | |
| Risk in group 2 | 0.325 | 0.264 | 0.392 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0202 | -0.108 | 0.0675 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.938 | 0.709 | 1.24 | log | |
| Odds ratio, group 1 over group 2 | 0.911 | 0.605 | 1.37 | log | |
| Number needed to treat, for one fewer participant with the outcome on Paliperidone ER than on Olanzapine | 49.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Paliperidone ER | 6-mg or 9-mg tablet once daily flexible dosing for 6 months | 68 | 223 | OG000 |
| Group 2 | Olanzapine | 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months | 66 | 203 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients With Impaired Fasting Glucose
- Description
- Post-baseline glucose level under fasted conditions ≥100 mg/dL but \<126 mg/dL.
- Time frame
- Baseline to End Point (up to 6 months)
- Population
The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.
Source ClinicalTrials.gov
Trial
- Title
- A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
- NCT number
- NCT00645099
- Phases
- PHASE3
- Conditions
- Schizophrenia
- Interventions
- olanzapine, paliperidone ER
- Lead sponsor
- Janssen-Cilag International NV
- Results first posted
- 2010-07-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00645099?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00645099-a8ed374e